Q&A on HIV PrEP: Episode 5 on Transgender Individuals and Racial and Ethnic Minority Men Who Have Sex With Men Part 2

In this episode, Aniruddha (Anu) Hazra, MD, and Ofole Mgbako, MD, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including:

• Data on drug–drug interactions between PrEP options and gender-affirming hormone therapy
• Contributing factors to inequities in PrEP uptake for Black and Latino individuals
• Data on FTC/TAF PrEP for transgender individuals
• How to decide whether to do an oral lead-in before starting injectable cabotegravir PrEP
• Time to effectiveness after starting PrEP
• PrEP resources available for transgender communities, especially regarding stigma
• Integration of PrEP with gender-affirming hormone therapy
• Strategies to increase PrEP uptake, specifically in the south
• Counseling patients on drug–drug interactions, adverse events, and transmission risk when starting PrEP
• Involving PrEP navigators in the care of people receiving PrEP
• Supporting PrEP adherence and retention in care
• The use of DoxyPEP in transgender individuals receiving PrEP

Faculty

Aniruddha (Anu) Hazra, MD
Assistant Professor, Section of Infectious Disease and Global Health
Director, Infectious Diseases Fellowship Program
Medical Director, UCM Sexual Wellness Clinic
Director of STI Services, Chicago Center of HIV Elimination
Department of Medicine
University of Chicago
Chicago, Illinois

Ofole Mgbako, MD
Assistant Professor of Medicine and Population Health
Section Chief of Infectious Disease
Bellevue Hospital
Clinical Pillar Lead, NYU Institute for Excellence in Health Equity
NYU Grossman School of Medicine
NYU Langone Health
New York, New York

Link to full program: https://bit.ly/3PZGYdR

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.